Hot Regional Bank Stocks To Own Right Now

Hot Regional Bank Stocks To Own Right Now: Seattle Genetics Inc.(SGEN)

Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc .; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.

Advisors' Opinion:

• [By Roberto Pedone]

  Another biotechnology player that insiders are loading up on here is Seattle Genetics (SGEN), which develops and commercializes antibody-based therapies for the treatment of cancer. Insiders are buying this stock into modest weakness, since shares are down by just 4.4% so far in 2014.

  Seattle Genetics has a market cap of $4.6 billion and an enterprise value of $4.3 billion. This stock trades at a premium valuation, with a price-to-sales of 16.7 and a price-to-book of 20.7. Its estimated growth rate for this year is -29.4%, and for next year it's pegged at 16.7%. This ! is a cash-rich company, since the total cash position on its balance sheet is $339.56 million and its total debt is zero.

  A director just bought 1,653,925 shares, or about $57.15 million worth of stock, at $33.71 to $36.57 per share.

  From a technical perspective, SGEN is currently trending above its 50-day moving average and just below its 200-day moving average, which is neutral trendwise. This stock has been uptrending over the last few weeks, with shares moving higher from its low of $32.63 to its intraday high of $38.70 a share. During that uptrend, shares of SGEN have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of SGEN within range of triggering a near-term breakout trade.

  If you're in the bull camp on SGEN, then I would look for long-biased trades as long as this stock is trending above some near-term support just below $36 a share and then once it breaks out above some near-term overhead resistance levels at $39.20 a share to its 200-day moving average of $40.33 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.09 million shares. If that breakout triggers soon, then SGEN will set up to re-test or possibly take out its next major overhead resistance levels at $42.18 to $42.39 a share,

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/hot-regional-bank-stocks-to-own-right-now.html